Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DXCM vs PEN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DXCM Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

DXCM Overall Winner 6-Pillar Tally: DXCM 5 – 1 PEN Matrix Metrics: DXCM 7 – 3 PEN

As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Penumbra, Inc. (PEN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas PEN carries 52.2/100 (HOLD) at $319.12 (53.1x Forward P/E, 12.1% operating margin).

  • Composite vs. Pillar Nuance: While PEN currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. DXCM 50.8/100 HOLD), DXCM captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (24.0% vs. 12.1% operating margin) and revenue trajectory (+11.2% vs. +15.6% YoY).
  • Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile PEN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 45.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DXCM vs PEN
DXCM NASDAQ Head-to-Head Winner
DexCom, Inc.
Surgical & Medical Instruments & Apparatus
$79.32
-1.08% 1D
Market Cap $29.9B
TTM Revenue $5.10B
Forward P/E 25.3x
Beta / 30D Vol 0.59β · 43% Vol
Unified Composite Score
50.8 / 100 HOLD
Tech 49.0 Fund 56.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.3%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $81.49 · SMA50: $83.94
PEN NYSE
Penumbra, Inc.
Surgical & Medical Instruments & Apparatus
$319.12
-0.28% 1D
Market Cap $12.6B
TTM Revenue $1.56B
Forward P/E 53.1x
Beta / 30D Vol 0.10β · 10% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 63.0 Mom 46.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.2%) with fading momentum, RSI 45
RSI-14: 45.0 · SMA20: $320.94 · SMA50: $320.21

6-Pillar Scorecard Institutional Category Breakdown (DXCM 5 – 1 PEN)

Columns: Metric · DXCM · PEN
1. Valuation Multiples DXCM
Forward P/E 25.3x 53.1x
Trailing P/E 31.6x 80.6x
PEG Ratio 1.30x 3.61x
EV / Revenue 5.9x 8.1x
2. Growth & Scale DXCM
Revenue Growth (YoY) +11.2% +15.6%
Earnings Growth (YoY) +2.6% -8.5%
TTM Revenue (USD) $5.10B $1.56B
Market Cap $29.9B $12.6B
3. Profitability & Quality DXCM
Gross Margin 63.4% 68.0%
Operating Margin 24.0% 12.1%
Net Profit Margin 19.4% 10.1%
Return on Equity (ROE) 37.7% 10.7%
4. Balance Sheet & Cash Flow DXCM
Cash Generation (TTM) $1.73B $200M
Cash Flow Margin 33.9% 12.8%
Net Cash / Leverage $432M Net Debt (0.55x D/E) $45M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DXCM
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 63.0% (15th %ile) 207.7% (96th %ile)
Put/Call OI Skew 0.48x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Distribution
6. R&D & Supply-Chain Moat PEN
OpEx & R&D Intensity 39.4% of Rev ($2.01B) 55.9% of Rev ($872M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DXCM (7) vs PEN (3)
Institutional Metric DXCM PEN Criterion Row Edge
Market Capitalization
Scale
$29.9B $12.6B Larger Scale DXCM
Trailing P/E Ratio
Valuation
31.6x 80.6x Lower Multiple DXCM
Forward P/E Ratio
Valuation
25.3x 53.1x Lower Multiple DXCM
Revenue Growth (YoY)
Growth
+11.2% +15.6% Higher Growth PEN
Operating Margin (TTM)
Profitability
24.0% 12.1% Higher Margin DXCM
Net Profit Margin
Profitability
19.4% 10.1% Higher Margin DXCM
Return on Equity (ROE)
Capital Efficiency
37.7% 10.7% Higher ROE DXCM
52-Week Range Position
Momentum
63% ($57–$93) 50% ($277–$362) Stronger Trend DXCM
Beta / 30D Volatility
Risk Regime
0.59β · 43% Vol 0.10β · 10% Vol Lower Realized Risk PEN
Unified Institutional Score
Composite Signal
50.8 / 100 (HOLD) 52.2 / 100 (HOLD) Higher Composite PEN
Trailing 12M Revenue (USD)
Operating Scale
$5.10B $1.56B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
63.4% 68.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.30x PEG · 5.9x EV/Rev 3.61x PEG · 8.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.73B ($432M Net Debt (0.55x D/E)) $200M ($45M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DXCM +3.08 pp
DXCM: +1.28% · PEN: -1.8%
3M Horizon PEN +11.46 pp
DXCM: -12.89% · PEN: -1.43%
6M Horizon DXCM +12.92 pp
DXCM: +10.01% · PEN: -2.91%
1Y Horizon DXCM +20.1 pp
DXCM: +32.8% · PEN: +12.7%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DXCM Revenue PEN Revenue DXCM Op. Margin PEN Op. Margin Margin Leader
FY2018 $1.03B $440M -18.1% -0.2% PEN
FY2019 $1.48B $550M 9.6% 8.7% DXCM
FY2020 $1.93B $560M 15.5% -6.9% DXCM
FY2021 $2.45B $750M 10.9% -1.0% DXCM
FY2022 $2.91B $850M 13.4% 0.7% DXCM
FY2023 $3.62B $1.06B 16.5% 6.9% DXCM
FY2024 $4.03B $1.19B 14.9% 0.8% DXCM
FY2025 $4.66B $1.40B 19.6% 13.5% DXCM

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DXCM CONSOLIDATION
73d in phase · OBV ACCUMULATION
Current IV 63.0%
IV Percentile 15th %ile
Put/Call OI Skew 0.48x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact DXCM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PEN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 207.7%
IV Percentile 96th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact PEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $81.61 · IV 39.6%

DXCM vs. PEN: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of DXCM ($8,161) vs. PEN ($31,969) against risk-defined 5-day vertical and put-wall option structures.

DXCM Spot $81.61 · IV 39.6%
DXCM Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $80 / $90 Bull Call Spread

Buy 1x $80C · Sell 1x $90C · 31d

Net Entry $482 Debit
T+5d @ +5% Move +$136 (+28%)
Max Risk / Buffer $482 Capped
5d Edge & Liquidity 0.7x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $75 / $70 Bull Put Spread

Sell 1x $75P · Buy 1x $70P · 31d

Net Entry $86 Credit
Max Credit / Yield +$86 (+20.8% RoM)
Max Risk / Buffer -9.2% Cushion ($414 Mgn)
5d Edge & Liquidity 78% PoP · Liq B
Simulate 5-Day Payoff →
PEN Spot $319.69 · IV 30.1%
PEN Options Simulator →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $290 / $260 Bull Put Spread

Sell 1x $290P · Buy 1x $260P · 31d

Net Entry $140 Credit
Max Credit / Yield +$140 (+4.9% RoM)
Max Risk / Buffer -9.7% Cushion ($2,860 Mgn)
5d Edge & Liquidity 81% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $320 / $300 Bear Put Spread

Buy 1x $320P · Sell 1x $300P · 31d

Net Entry $750 Debit
T+5d @ -5% Drop +$425 (+57%)
Max Risk / Buffer $750 Capped
5d Edge & Liquidity 1.0x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DXCM Moat Profile High-Margin Pricing Power Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $29.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 39.4% of Rev ($2.01B)
90D Engineering Disclosures 0 Published
PEN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $12.6B market capitalization and 12.1% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($872M)
90D Engineering Disclosures 0 Published

Investor FAQ DXCM vs PEN Key Questions & Quantitative Answers

As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Penumbra, Inc. (PEN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas PEN carries 52.2/100 (HOLD) at $319.12 (53.1x Forward P/E, 12.1% operating margin). Composite vs. Pillar Nuance: While PEN currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. DXCM 50.8/100 HOLD), DXCM captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (24.0% vs. 12.1% operating margin) and revenue trajectory (+11.2% vs. +15.6% YoY). Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile PEN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 45.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DXCM leads the Growth & Scale pillar: DXCM posts +11.2% YoY revenue growth and +2.6% YoY earnings growth on $5.10B TTM revenue (63.4% gross margin, 24.0% operating margin), compared with PEN at +15.6% YoY revenue growth and -8.5% YoY earnings growth on $1.56B TTM revenue (68.0% gross margin, 12.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DXCM cumulative revenue shifted +352.4% while PEN shifted +218.2%. In operating R&D and SG&A reinvestment, DXCM deploys 39.4% of Rev ($2.01B) (0 90-day corporate R&D disclosures) versus 55.9% of Rev ($872M) (0 disclosures) for PEN.

DXCM screens cheaper on headline valuation multiples. DXCM trades at 25.3x Forward P/E, 31.6x Trailing P/E, 1.30x PEG, and 5.9x EV/Revenue (33.9% FCF margin), whereas PEN trades at 53.1x Forward P/E, 80.6x Trailing P/E, 3.61x PEG, and 8.1x EV/Revenue (12.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DXCM (37.7% ROE) versus PEN (10.7% ROE) capital efficiency.

In options market volatility and institutional positioning, DXCM carries 63.0% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.48x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.59β · 43% Vol realized risk). By comparison, PEN carries 207.7% implied volatility (96th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.10β · 10% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.